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Aim. To perform the comparative study both of qualitative and quantitative content of lipids in parental and drug resistant breast cancer 
cells. Materials and methods. Parental (MCF-7/S) and resistant to cisplatin (MCF-7/CP) and doxorubicin (MCF-7/Dox) human breast 
cancer cells were used in the study. Cholesterol, total lipids and phospholipids content were determined by means of thin-layer chroma-
tography. Results. It was found that cholesterol as well as cholesterol ethers content are significantly higher but diacylglycerols, triacyl-
glycerols content are significantly lower in resistant cell strains than in parental (sensitive) cells. Moreover the analysis of individual 
phospholipids showed the increase of sphingomyelin, phosphatidylserine, cardiolipin, phosphatidic acid and the decrease of phosphatidy-
lethanolamine, phosphatidylcholine in MCF-7/CP and MCF-7/Dox cells. Conclusion. Obtained results allow to suggest that the lipid 
profile changes can mediate the modulation of membrane fluidity in drug resistant MCF-7 breast cancer cells.
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Much attention has been recently paid to the lipid-
protein interactions as an important component in the 
biochemical state and the regulation of cellular vital ac-
tivity [1–4]. These phenomena become of particular 
importance in the process of transforming normal cells 
into malignant. The notion of so-called membrane-lipid 
therapy has even been formulated, which aims to develop 
drugs that affect the lipid organization and can modulate 
the localization and activity of membrane proteins [5, 6]. 
Lipids not only affect the structure of membranes, but also 
fulfill the relevant regulatory functions in normal and tumor 
cells. For example, some protein kinase C isoenzymes 
are activated by phosphatidylserine, phosphatidyletha-
nolamine and diacylglycerol [7–10]. Phosphoinositides, 
namely phosphatidylinositol, take a direct part in the 
operation of certain signal pathways in the cell and Ca2+-
transport [11]. Negatively charged phosphatidylserine 
regulates the electrostatic interaction between proteins 
and membranes [5], and some lipid domains in mem-
branes are peculiar temperature sensors during the 
reaction of cells to heat shock [12]. According to several 
studies there is a significant difference in lipid composi-
tion for normal and tumor cells of the same histogenesis 
[13–17]. Thus, the existence of the differences in the level 
of phosphatidylcholine (PC), phosphatidylethanolamine 
(PE), phosphatidylserine (PS), sphingomyelin (SM) and 
phosphatidylinositol (PI) has been shown by T.E. Merchant 
et al. during the comparative study of the lipid content 
of normal breast tissue cells and tissues of benign as well 
malignant tumors of human breast by the use of 31P NMR 
spectroscopy [16]. The same authors found that low-
grade differentiated and high-grade differentiated tumors 
vary in level of PC in colon cancer cells [14]. It was shown 
that the reduction of cholesterol was observed in Mor-
ris 5123 hepatoma cell membranes in comparison with 
hepatocytes[17].
Besides, the results of our previous studies have 
shown that changes in lipid composition of tumor 
cells also occur during the process of drug resistance 
phenotype development. So in particular, some diffe-
rences in the phospholipid content of cell membranes 
of parental and doxorubicin-resistant Guerin carci-
noma were found [18, 19]. These data indicate that 
some minor phospholipids may play an important role 
in the development of tumor drug resistance. Thus 
due to the resistance development a malignant cell 
acquires new properties which are reflected on the 
both morphological level and change of its molecular 
and biochemical characteristics [20].
Taking into account above mentioned the study 
of qualitative and quantitative lipid composition 
of sensitive and resistant malignant cells is relevant. 
It can allow to clarify the mechanisms of tumor cells 
resistance formation and to argue for the expedient 
using of liposomal forms of anticancer drugs that could 
probably increase the efficacy of anticancer therapy.
MATERIALS AND METHODS
Cell strains and cell cultivation. The cells of the 
parental MCF-7/S strain were cultivated  in the Dulbecco 
ISCOVE modified medium (Sigma-Aldrich Chemie 
GmbH, Germany) supplemented with 10% fetal calf 
serum (“Sangva”, Ukraine) at 37◦C and saturated air 
with 5% CO2. The cells were subcultured twice a week 
with a 2–4x104 cells/cm2 surface plating density. Cell 
lines resistant to the action of anticancer drugs (MCF-7/
CP — resistant to cisplatin and MCF-7/Dox — resistant 
to doxorubicin) were obtained as presented earlier [24].
Thin-layer chromatography method. The 
qualitative and quantitative composition of total lipids 
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and phospholipids were determined by thin-layer 
chromatography method using plates “Sorbfil” PTSH-
AF-A (“Imid Ltd”, Krasnodar, Russia). To realize this 
purpose the lipids from the MCF-7/S, MCF-7/CP and 
MCF-7/Dox cells were extracted using a chloroform/
methanol solvent mixture (1:1, v/v). The thin-layer 
chromatography of total lipids was carried out only 
in one direction in the hexane/diethyl ether/glacial 
acetic acid solvent system (85:15:1, v/v) [21]. The 
thin-layer chromatography of phospholipids was car-
ried out in two mutually perpendicular directions [22]. 
The first solvent system was chloroform/methanol/
benzene/ammonia (65:30:10:6, v/v). The second 
system was chloroform/methanol/benzene/acetone/
glacial acetic acid/water (70:30:10:5:4:1, v/v). After 
the evaporation of the solvent system the plates were 
treated with 10% H2SO4 in methanol and heated for 
5 min at 180 ◦C. All chromatograms were scanned and 
scans were imaged with the program Picture J. Lipid 
content was expressed in percents. Seven experi-
ments with each cell line were performed in this study. 
The statistical analysis of the results was carried out 
using Student’s test. Differences were consi dered 
significant at p<0.05.
RESULTS AND DISCUSSION
Results presented in Table 1 show marked diffe-
rences in the total lipid composition between sensitive 
and resistant MCF-7 cell strains. It has to be marked 
that used method didn’t allow to determine free fatty 
acids in resistant cells. It was shown (see Table 1) the 
significant increase of cholesterol  in the MCF-7 cells 
resistant to cisplatin and doxorubicin by 60 and 55%, 
respectively (P<0,05). At the same time in the MCF-7/
CP and MCF-7/Dox cells the increase of cholesterol 
esters content was recorded. Formation of drug resis-
tance phenotype in human breast cancer cells is also 
accompanied with significant quantitative changes 
of mono-, di- and triacylglycerols. For example, 
in the cells of both resistant strains a much smaller 
number of monoacylglycerols in comparison with 
the cells of sensitive strain (P<0,05) was observed. 
In the MCF-7/CP cells the amount of monoacylglyc-
erols was reduced by 3.7 fold and in the MCF-7/Dox 
cells by 3.4 fold. The reduction of diacylglycerols and 
triacyl glycerols amount in the cells of both resistant 
strains was also recorded.
Table 1. The content of total lipids (%) in sensitive and resistant 
MCF-7 strain cells (n = 7)
Lipids MCF-7/S MCF-7/CP MCF-7/Dox
Phospholipids (PL) 12.7±1.0 17.7±1.0 ▲ 18.7±1.3 ▲
Моnoacylglycerols (МG) 6.7±0.1 1.8±0.2 ▼ 2.0±0.4 ▼
Cholesterol (Ch) 18.1±1.8 29.0±0.8 ▲ 28.2±1.4 ▲
Free fatty acids (FFA) 5.6±0.1 0 ▼ 0 ▼
Diacylglycerols (DG) 19.4±0.7 17,6±0.6 15.0±0.5 ▼
Тriacylglycerols (TG) 29.6±0.9 8.3±0.7 ▼ 18.1±0.4 ▼
Cholesterol ethers (ChE) 7.9±1.2 25.6±0.7 ▲ 18.0±1.8 ▲
Note: ▲— significantly higher (P<0.05) than in MCF-7/S cells; ▼ — signifi-
cantly lower (P<0.05) than in MCF-7/S cells
We also found that the total content of phospholipids 
is higher in resistant cells than in sensitive ones. The 
individual phospholipid analysis of MCF-7/S, MCF-7/
CP MCF-7/Dox cells has shown that the resistant cells 
compared with sensitive cells contain more SM and phos-
phatidylglycerol (Table 2) and, conversely, less PE. Also, 
the increase of cardiolipin (diphosphatidyl glycerol) level 
in resistant cells (especially in MCF-7/CP) was notewor-
thy. It is known that cardiolipin is localized both on the 
inner and outer mitochondrial membrane sheets and 
in contact places of eukaryotic cells. This substance 
is necessary for the catalytic activity of several enzymes 
involved in energy metabolism (provides the coupling 
of oxidative phosphorylation in mitochondria [23]). The 
interaction of cardiolipin with mitochondrial proteins 
is specific. Acylic cardiolipin composition is an important 
factor that provides the functional reactivation of mito-
chondrial enzymes, such as cytochrome-c-oxidase. 
Moreover, acylic cardiolipin composition plays a key role 
in the initiation of apoptosis (cit. [23]).
Table 2. The content of phospholipids (%) in sensitive and resistant cells 
of MCF-7 strain (n = 7)
Lipids MCF-7/S MCF-7/CP MCF-7/Dox
Lisophosphatidylcholine (LPC) 5.6±0.4 6.5±0.9 5.9±0.4
Sphingomielyn (SM) 7.6±0.4 12.0±0.5 ▲ 9.8±0.2 ▲
Phosphatidylserine (PS) 6.7±0.4 8.8±0.6 ▲ 9.4±0.6 ▲
Phosphatidylinositol (PI) 8.4±0.2 7.3±1.0 8.8±0.7
Phosphatidylcholine (PC) 39.4±2.4 30.2±3.0 ▼ 30.2±3.1 ▼
Phosphatidylethanolamine (PE) 16.4±0.3 11.8±0.3 ▼ 12.8±0.6 ▼
Cardiolipin (CL) 6.7±0.3 9.2±0.4 ▲ 8.6±0.2 ▲
Phosphatidic acid (PA) 4.4±0.7 6.8±0.2 ▲ 7.4±0.3 ▲
Phosphatidylglycerol (PG) 4.8±0.3 7.4±0.3 ▲ 7.1±0.2 ▲
Note: ▲ — significantly higher (P<0.05) than in MCF-7/S cells; ▼ — signifi-
cantly lower (P<0.05) than in MCF-7/S cells
The higher level of phosphatidic acid and phosphati-
dylserine was defined in the MCF-7/CP and MCF-7/Dox 
cells comparatively to MCF-7/S cells. Phosphatidic acid 
is an important point of branching in the biosynthesis 
of various phospholipids (Fig. 1). Thus, the synthesis 
of PC, PE and phosphatidylserine is carried out as a re-
sult of the hydrolysis of phosphatidic acid and diacyl-
glycerol formation under the influence of phosphatidic 
acid phosphatase. Another variant of phosphatidic acid 
metabolism is its conversion into CDP-diacylglycerol 
which is used in biosynthesis of PI, phosphatidylglycerol 
and cardiolipin [23].
In accordance with well known data about metabo-
lism of phospholipids we would also like to mention that 
the differences between sensitive and resistant cells 
in lisophosphatidylcholine (LPC) and PI content were 
not observed in our study.
Thus, we found that the formation of resistance 
to anticancer drugs is accompanied by changes in the 
composition of lipids in MCF-7 human breast cancer 
cells. The increase of cholesterol and SM content 
causes as known the decrease of cell membrane fluid-
ity. This assumption is also confirmed by determination 
of the PC/SM ratio. PC and SM adapt mainly lamellar 
configuration of cell membrane and, therefore, sig-
nificantly influence the membrane stability and fluidity. 
The content of PC in resistant cells was decreased 
and SM — increased. Therefore as seen from the data 
presented in Table 3, the PC/SM ratio in the MCF-7/
CP and MCF-7/Dox cells is significantly lower than the 
same one in sensitive MCF-7/S cells that can indicate 
the decrease of resistant cells membrane fluidity.
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Table 3. The PC/SM ratio in MCF-7 cells (n=7)
MCF-7/S MCF-7/CP MCF-7/Dox
5.2±0.3 2.5±0.4 ▼ 3.1±0.3 ▼
Note: ▼ — significantly lower (P<0.05) than in MCF-7/S cells.
In general, paying attention to the change of cho-
lesterol and SM amounts in resistant cells, it is worth 
to say about lipid rafts. Lipid rafts are peculiar areas 
within the outer sheet of plasma membrane that are 
enriched with cholesterol and sphingolipids. They 
are able to selectively incorporate proteins, modify 
protein-protein and protein-lipid interactions. These 
membrane microdomains participate in the processes 
of membranes invagination, signal transduction, en-
docytosis (cit. [23]). 
To explain the obtained results we used the scheme 
persented in the Fig. 1. It can be seen from the scheme 
that an increase of phosphatidic acid and phosphati-
dylserine level is fixed in resistant cells. This situation 
should result in the increase of PE and respectively 
to the increase of PC. However, we don’t observe such 
one. On the contrary, the level of last phospholipids 
in the resistant cells becomes lower comparatively 
to basestrain ones. On the one hand, cell maligniza-
tion is often accompanied by hyperhomocystein-
emia, which results in the disruption of methylation 
processes (i.e., to hypomethylation), that it was 
shown in our previous works [24, 25]. On the other 
hand, perhaps, an inhibition of phosphatidylserine 
decarboxylation occurs, which leads to the decrease 
of PE. Along with this, in resistant cells probably also 
an inhibition of PC synthesis through “diacylglycerol 
way” carries out.
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Fig. 1. Scheme of the biosynthesis of certain phospholipids. “+” 
and “-” means increase or decrease of the corresponding lipids 
in resistant MCF-7 cells
We suppose that the increase of cholesterol and 
SM content results in the decrease of membrane flu-
idity, and the increase of phosphatidylserine results 
in the activation of the cytotoxic substances elimina-
tion by means of P-glycoprotein, that is in accordance 
with literature data [25–27]. The obtained data are also 
confirmed by our previous results and the data of other 
authors [18, 19, 28]. So, we have proved the role 
of lipid component in the formation of drug resistance 
phenotype in malignant cells. We would like to pres-
ent the hypothetical scheme of membrane in drug 
resistant cells (Fig. 2). These data may be used for the 
development of new forms of anticancer drugs which 
could significantly improve the efficacy of cytostatics 
through overcome drug resistance.
Sensitive cell membrane
Resistant cell membrane
Saturated phospholipids
Unsaturated phospholipids
Sphingomyelin
Cholesterol
Proteins
Fig. 2. Structural organization of chemotherapy drugs resistant 
cell membranes
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